Contents

Search

ROS1 gene mutation; ROS1 gene fusion; ROS1 gene rearrangement

Indications: - evaluation of non-small cell lung cancer (NSCLC) [1,2] Clinical significance: - ROS1 gene rearrangements in 2% of NSCLC [1] - lower rates of extrathoracic NSCLC metastases, including fewer brain metastases compared with ALK gene rearrangements

Related

proto-oncogene tyrosine-protein kinase ROS; c-ros protein; p53ros; mcf3 tyrosine kinase receptor; c-ros-1 (ROS1) ros proto-oncogene, ros1 proto-oncogene or mcf1 proto-oncogene

General

gene mutation testing; gene mutation analysis

References

  1. Pal S. Crizotinib Tx Stakes Claim in ROS1-Positive NSCLC. The TKI boosts outcomes in those with a rare disease -- enough to convince FDA to approve the agent fast and early. MedPage Today. ASCO Reading Room. Feb 9, 2018 https://www.medpagetoday.com/reading-room/asco/lung-cancer/71049 - Gainor JF, Tseng D, Yoda S et al Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small cell lung cancer. JCO Precision Oncology. Epub 2017 Aug 16. PMID: 29333528 Free PMC Article
  2. ARUP Consult: Lung cancer deprecated reference